Altimmune Statistics
Total Valuation
Altimmune has a market cap or net worth of $604.81 million. The enterprise value is $309.12 million.
| Market Cap | 604.81M |
| Enterprise Value | 309.12M |
Important Dates
The next estimated earnings date is Tuesday, August 11, 2026, before market open.
| Earnings Date | Aug 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Altimmune has 194.47 million shares outstanding. The number of shares has increased by 38.98% in one year.
| Current Share Class | 194.47M |
| Shares Outstanding | 194.47M |
| Shares Change (YoY) | +38.98% |
| Shares Change (QoQ) | +23.70% |
| Owned by Insiders (%) | 0.44% |
| Owned by Institutions (%) | 42.68% |
| Float | 164.20M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 16,800.41 |
| Forward PS | 144,003.48 |
| PB Ratio | 1.43 |
| P/TBV Ratio | 2.13 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 8,586.71 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 29.56, with a Debt / Equity ratio of 0.13.
| Current Ratio | 29.56 |
| Quick Ratio | 29.43 |
| Debt / Equity | 0.13 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -35.59 |
Financial Efficiency
Return on equity (ROE) is -42.75% and return on invested capital (ROIC) is -25.94%.
| Return on Equity (ROE) | -42.75% |
| Return on Assets (ROA) | -24.40% |
| Return on Invested Capital (ROIC) | -25.94% |
| Return on Capital Employed (ROCE) | -29.67% |
| Weighted Average Cost of Capital (WACC) | 5.60% |
| Revenue Per Employee | $632 |
| Profits Per Employee | -$1.60M |
| Employee Count | 57 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -29.80% in the last 52 weeks. The beta is 0.24, so Altimmune's price volatility has been lower than the market average.
| Beta (5Y) | 0.24 |
| 52-Week Price Change | -29.80% |
| 50-Day Moving Average | 2.89 |
| 200-Day Moving Average | 3.85 |
| Relative Strength Index (RSI) | 59.51 |
| Average Volume (20 Days) | 4,976,189 |
Short Selling Information
The latest short interest is 41.93 million, so 21.56% of the outstanding shares have been sold short.
| Short Interest | 41.93M |
| Short Previous Month | 39.12M |
| Short % of Shares Out | 21.56% |
| Short % of Float | 25.53% |
| Short Ratio (days to cover) | 14.95 |
Income Statement
In the last 12 months, Altimmune had revenue of $36,000 and -$91.08 million in losses. Loss per share was -$0.91.
| Revenue | 36,000 |
| Gross Profit | -66.05M |
| Operating Income | -96.21M |
| Pretax Income | -91.08M |
| Net Income | -91.08M |
| EBITDA | -96.10M |
| EBIT | -96.21M |
| Loss Per Share | -$0.91 |
Balance Sheet
The company has $331.54 million in cash and $35.85 million in debt, with a net cash position of $295.69 million or $1.52 per share.
| Cash & Cash Equivalents | 331.54M |
| Total Debt | 35.85M |
| Net Cash | 295.69M |
| Net Cash Per Share | $1.52 |
| Equity (Book Value) | 283.99M |
| Book Value Per Share | 2.18 |
| Working Capital | 323.35M |
Cash Flow
In the last 12 months, operating cash flow was -$71.64 million and capital expenditures -$32,000, giving a free cash flow of -$71.67 million.
| Operating Cash Flow | -71.64M |
| Capital Expenditures | -32,000 |
| Depreciation & Amortization | 106,000 |
| Net Borrowing | 35.00M |
| Free Cash Flow | -71.67M |
| FCF Per Share | -$0.37 |
Margins
| Gross Margin | n/a |
| Operating Margin | -267,247.22% |
| Pretax Margin | -253,002.78% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Altimmune does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -38.98% |
| Shareholder Yield | n/a |
| Earnings Yield | -15.06% |
| FCF Yield | -11.85% |
Analyst Forecast
The average price target for Altimmune is $15.45, which is 396.79% higher than the current price. The consensus rating is "Buy".
| Price Target | $15.45 |
| Price Target Difference | 396.79% |
| Analyst Consensus | Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (3Y) | 281.57% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on September 14, 2018. It was a reverse split with a ratio of 1:30.
| Last Split Date | Sep 14, 2018 |
| Split Type | Reverse |
| Split Ratio | 1:30 |
Scores
Altimmune has an Altman Z-Score of 2.35 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.35 |
| Piotroski F-Score | 3 |